Could Probiodrug Represent A New Era Of Alzheimer's R&D Progress?
Executive Summary
Probiodrug believes it can bring success to an Alzheimer's research community that has been hard hit by clinical failures in the last few years – but the company will need a partner or cash influx to take its first-in-class drug through late-stage trials.
You may also be interested in...
Axovant's Cupboard Is Bare After Lead Dementia Program Fails
'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.
Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study
In another blow for the amyloid hypothesis in Alzheimer's disease, Merck ended its pivotal EPOCH study for the BACE inhibitor verubecestat based on an interim assessment that there was "virtually no chance of finding a positive clinical effect" in the nearly completed Phase II/III clinical trial.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.